Innovative Pharmaceutical Biotech Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Innovative Pharmaceutical Biotech.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Trade Distributors kazanç büyümesi	7.3%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Aug 12

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

Jan 05

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Feb 18

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Nov 26

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Innovative Pharmaceutical Biotech yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

SEHK:399 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (HKD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2024	7	103	-8	-8	N/A
12/31/2023	7	84	-14	-14	N/A
9/30/2023	8	64	-19	-19	N/A
6/30/2023	8	-91	-18	-18	N/A
3/31/2023	8	-246	-18	-18	N/A
12/31/2022	8	-220	-9	-9	N/A
9/30/2022	9	-195	0	0	N/A
6/30/2022	10	-75	-6	-6	N/A
3/31/2022	11	46	-12	-12	N/A
12/31/2021	13	30	-21	-21	N/A
9/30/2021	15	14	-31	-31	N/A
6/30/2021	15	-96	-28	-28	N/A
3/31/2021	15	-205	-25	-25	N/A
12/31/2020	13	-200	-28	-28	N/A
9/30/2020	11	-194	-32	-32	N/A
6/30/2020	13	-203	-34	-34	N/A
3/31/2020	15	-211	-36	-36	N/A
12/31/2019	17	-205	-41	-41	N/A
9/30/2019	20	-199	-45	-45	N/A
6/30/2019	19	-230	-37	-37	N/A
3/31/2019	19	-260	-29	-29	N/A
12/31/2018	17	-258	3	3	N/A
9/30/2018	16	-256	35	35	N/A
6/30/2018	16	-243	10	10	N/A
3/31/2018	16	-231	-15	-15	N/A
12/31/2017	14	-237	N/A	-17	N/A
9/30/2017	13	-243	N/A	-19	N/A
6/30/2017	11	-206	N/A	51	N/A
3/31/2017	9	-170	N/A	120	N/A
12/31/2016	10	-196	N/A	48	N/A
9/30/2016	11	-223	N/A	-24	N/A
6/30/2016	16	-230	N/A	-79	N/A
3/31/2016	20	-237	N/A	-133	N/A
12/31/2015	25	-214	N/A	-80	N/A
9/30/2015	31	-190	N/A	-26	N/A
6/30/2015	32	-321	N/A	-31	N/A
3/31/2015	34	-452	N/A	-36	N/A
9/30/2014	41	-891	N/A	-60	N/A
6/30/2014	39	-730	N/A	-64	N/A
3/31/2014	36	-569	N/A	-67	N/A
12/31/2013	31	-522	N/A	-51	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if 399's forecast earnings growth is above the savings rate (2.3%).

Kazançlar ve Piyasa: Insufficient data to determine if 399's earnings are forecast to grow faster than the Hong Kong market

Yüksek Büyüme Kazançları: Insufficient data to determine if 399's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if 399's revenue is forecast to grow faster than the Hong Kong market.

Yüksek Büyüme Geliri: Insufficient data to determine if 399's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if 399's Return on Equity is forecast to be high in 3 years time

Innovative Pharmaceutical Biotech Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending 30 September 2022

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending September 30, 2021

Recent updates

Full year 2024 earnings released: EPS: HK$0.068 (vs HK$0.17 loss in FY 2023)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 29, 2024

New minor risk - Share price stability

Full year 2024 earnings released: EPS: HK$0.068 (vs HK$0.17 loss in FY 2023)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2024 Results on Jun 28, 2024

Innovative Pharmaceutical Biotech Limited has filed a Follow-on Equity Offering in the amount of HKD 19.95 million.

First half 2024 earnings released: EPS: HK$0.13 (vs HK$0.079 loss in 1H 2023)

New major risk - Financial position

Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023

Innovative Pharmaceutical Biotech Limited to Report First Half, 2024 Results on Nov 29, 2023

Innovative Pharmaceutical Biotech Limited (SEHK:399) entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc.

New minor risk - Share price stability

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2023

Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending 30 September 2022

Innovative Pharmaceutical Biotech Limited to Report First Half, 2023 Results on Nov 29, 2022

Less than half of directors are independent

Full year 2022 earnings released: EPS: HK$0.031 (vs HK$0.14 loss in FY 2021)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2022

Innovative Pharmaceutical Biotech Ordinary Shares to Be Deleted from Other OTC

Full year 2022 earnings released

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2022

Less than half of directors are independent

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending September 30, 2021

Full year 2021 earnings released: HK$0.14 loss per share (vs HK$0.14 loss in FY 2020)

New 90-day high: HK$0.28

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Innovative Pharmaceutical Biotech Limited Announces Executive Changes

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Innovative Pharmaceutical Biotech Limited to Report First Half, 2021 Results on Nov 27, 2020

Innovative Pharmaceutical Biotech Limited Announces Board Changes

New 90-day high: HK$0.27

New 90-day high - HK$0.26

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

Full year earnings released - HK$0.14 loss per share

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin